General Information
Revision date
2022-12-13
Product name
Atellica CH Uric Acid (UA)
1.2.1 Relevant identified uses
UA R1 Reagent Diagnostic agents UA R2 Reagent Diagnostic agents
supplier name
Siemens Healthcare Diagnostics Limited
Emergency telephone
+44 20 3807 3798
Icons in SDS
Company Information
company name
Siemens Healthcare Diagnostics Limited
e-mail address of the competent person responsible for the Safety Data Sheet
dx.msds.healthcare@siemens-healthineers.com
GHS Information
Signal word
UA R1 Reagent
Section 2
SECTION 2: Hazards identification
Classification of the substance or mixture
Product definition
UA R1 Reagent Mixture UA R2 Reagent Mixture Classification according to UK CLP/GHS Not classified
Signal word
UA R1 Reagent No signal word. UA R2 Reagent No signal word.
Hazard statements
UA R1 Reagent No known significant effects or critical hazards. UA R2 Reagent No known significant effects or critical hazards.
Prevention
UA R1 Reagent Not applicable. UA R2 Reagent Not applicable.
Response
UA R1 Reagent Not applicable. UA R2 Reagent Not applicable.
Storage
UA R1 Reagent Not applicable. UA R2 Reagent Not applicable.
Disposal
UA R1 Reagent Not applicable. UA R2 Reagent Not applicable.
Supplemental label elements
UA R1 Reagent Not applicable. elements UA R2 Reagent Not applicable. Annex XVII - Restrictions UA R1 Reagent Not applicable. on the manufacture, UA R2 Reagent Not applicable. placing on the market and use of certain dangerous substances, mixtures and articles
2.3 Other hazards
Product meets the criteria UA R1 Reagent This mixture does not contain any for PBT or vPvB according substances that are assessed to be a to Regulation (EC) No. PBT or a vPvB.
Additional information
Not available. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides.
2.1 Classification of the substance or mixture
Product definition : UA R1 Reagent Mixture UA R2 Reagent Mixture Classification according to UK CLP/GHS Not classified. The product is not classified as hazardous according to UK CLP Regulation SI 2019/720 as amended. See Section 11 for more detailed information on health effects and symptoms.